Oculentis Recalls Lentis IOLs in Philippines Due to Reports of Postoperative Opacification

November 10, 2017: By Joan McKenna

1 Ophthalmic NewsBerlin-based Oculentis has issued a voluntary recall in the Philippines for all Lentis intraocular lenses distributed and imported by Ophthaswissmed Philippines, Inc., with an expiration date of January 2017 to May 2020. The Philippines Food and Drug Administration (FDA) issued an advisory Oct. 27.

The agency said Oculentis has received notifications of sporadic late postoperative opacification of the lenses, which may compromise the transparency of the lens over time, potentially leading to reduced visual acuity.

The Philippines FDA said studies by Oculentis indicate that the opacification may be caused by phosphate remnants from a cleaning agent used in production.

The recall covers the Lentis (MDR-04652), Lentis Comfort (MDR-04654), Lentis T Plus (MDR-04647), Lentis T Plus X (MDR-04707), Lentis Comfort Toric (MDR-04708), Lentis M Plus (MDR-04651), Lentis M Plus X (MDR-04653), Lentis M Plus Toric (MDR-04719), and the Lentis M Plus X Toric (MDR-04706).

Oculentis says Lentis IOLs with an expiration of June 2020 or later are unaffected.

The recall notice did not specify whether lenses in other countries are affected or other regulatory bodies have been notified. Oculentis did not respond to a request for additional information.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Imprimis’ Q3-2017 Ophthalmic Revenues Increase 60 Percent, Total $4.9 Million

iVeena Completes Phase I/IIa Study of IVMED-10 for Post-Cataract Inflammation

RegeneRx Announces Positive Phase III Results for RGN-259 in Dry Eye

Bill Link, PhD, Joins LENSAR as Board Chairman

Apellis Prices $150 Million Initial Public Offering

Oculentis Recalls Lentis IOLs in Philippines Due to Reports of Postoperative Opacification

Valeant Reports 1 Percent Growth for Bausch + Lomb Segment in Q3-2017

Tivanisiran is Generic Name for Sylentis’ Dry Eye Candidate

Alimera’s Q3-2017 Revenues Increased 18 Percent; Company Sees Expanded Market for Iluvien

Iridex’ Revenues Increase 11 Percent in Q3-2017; 111 Cyclo G6 Systems, 7,800 G6 Probes Shipped

Glaukos’ Net Sales Increase 37 Percent in Q3-2017

Regeneron’s US Eylea Sales Increase 12 Percent in Q3-2017

Second Sight Reports Q3-2017 Net Sales of $1.6 Million, New $122,500 CMS Rate for Argus II

Tear Film Innovations, Exicure, Genisphere Complete Financing Rounds

Opternative Sues Warby Parker Over Online Eye Exams

Bausch + Lomb Receives US FDA Approval for Vyzulta for IOP Reduction in Glaucoma Patients

Allergan Plans Cost Cuts, Takes Impairment Charge as Restasis Generics Loom

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022